

CLAIMS:

1. A composition for nasal absorption comprising a carrier of calcium carbonate and/or calcium phosphate having an average particle size of 500 μm or less and an effective dose of an opioid analgesic uniformly distributed and attached to the carrier.
2. A composition for nasal absorption according to claim 1 wherein the opioid analgesic is a narcotic or a non-narcotic opioid analgesic.
3. A composition for nasal absorption according to claim 1 or 2 wherein the opioid analgesic is a narcotic opioid analgesic selected from opium, opium/ipecac preparation, morphine, morphine/atropine preparation, opium alkaloids preparation, opium alkaloids/atropine preparation, opium alkaloids/scopolamin preparation, ethylmorphine, oxycodon, oxycodon/atropine preparation, pethidine, pethidine/levallorphan preparation, codeine, dihydrocodeine, fentanyl, droperidol/fentanyl preparation, oxymetebanol, levorphanol, propoxyphene, methadone, hydromorphone, and meperidine; or a non-narcotic opioid analgesic selected from buprenorphine, butorphanol, pentazocine, pentazocine/naloxone preparation, dezocine, tramadol, and eptazocine; or a pharmaceutically acceptable salt thereof.
4. A composition for nasal absorption according to claim 1 or 2 wherein the opioid analgesic is a narcotic opioid analgesic selected from opium, opium/ipecac preparation, morphine hydrochloride, morphine sulfate, morphine hydrochloride/atropine sulfate preparation, opium alkaloids hydrochloride preparation, opium alkaloids hydrochloride/atropine sulfate preparation, opium alkaloids hydrochlorides/scopolamine hydrobromide preparation, ethylmorphine hydrochloride, compound oxycodone (oxycodone

hydrochloride/hydrocotarnine hydrochloride), compound oxycodone/atropine sulfate preparation, pethidine hydrochloride, pethidine hydrochloride/levallorphan tartrate preparation, codeine phosphate, dihydrocodeine phosphate, fentanyl, fentanyl citrate, droperidol/fentanyl citrate preparation, oxymetebanol, levorphanol, propoxyphene, methadone, hydromorphone, and meperidine; or a non-narcotic opioid analgesic selected from buprenorphine hydrochloride, butorphanol tartrate, pentazocine, pentazocine hydrochloride, pentazocine hydrochloride/naloxone preparation, dezocine, tramadol hydrochloride, and eptazocine hydrobromide.

5. A composition for nasal absorption according to claim 1 or 2 wherein the opioid analgesic is morphine hydrochloride, morphine sulfate, morphine hydrochloride/atropine sulfate preparation, fentanyl, fentanyl citrate, droperidol/fentanyl citrate preparation, or buprenorphine hydrochloride, and the carrier is calcium carbonate.

6. A composition for nasal absorption according to any one of claims 1 to 5 wherein the carrier has an average particle size of 20 to 100 μm .

7. A composition for nasal absorption according to any one of claims 1 to 6 wherein content of the opioid analgesic is 0.01 to 50% by weight, and content of the carrier is 50 to 99.99% by weight.

8. A composition for nasal absorption according to any one of claims 1 to 7 wherein the opioid analgesic is an analgesic for post-surgery pain or cancer pain.

9. Use of a composition for nasal absorption in producing an analgesic for post-surgery pain or cancer pain,

wherein said composition comprises a carrier of calcium carbonate and/or calcium phosphate having an average particle size of 500 μm or less and an effective dose of an opioid analgesic uniformly distributed and attached to the carrier.

10. A method for treating post-surgery pain or cancer pain comprising the step of intranasally administering a composition comprising a carrier of calcium carbonate and/or calcium phosphate having an average particle size of 500 μm or less and an effective dose of an opioid analgesic uniformly distributed and attached to the carrier.